deCODE genetics: A sequence variant that increases risk of pregnancy loss
REYKJAVIK, Iceland, Jan. 29, 2024 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and theUSA published a study today in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates ...
Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
REYKJAVIK, Iceland, Nov. 6, 2023 /PRNewswire/ -- A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and somatic and germline genetics of clonal hematopoiesis. Whole genome sequence data fromIceland and...
Large-scale proteomics in population-based studies from UK and Iceland
REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome an...
deCODE genetics: Predicting the probability of death
REYKJAVIK, Iceland, June 18, 2021 /PRNewswire/ -- Scientists from deCODE
genetics have developed a predictor based on protein measurements in blood
samples that predicts the time to all-cause death better than traditional risk
factors.
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Several Other Inflammatory Diseases Moderate-to-Severe Atopic Dermatitis Affects Nearly 30 Mill...
Loss of Function Variant in FLT3 Strongly Increases the Risk of Autoimmune Thyroid Disease and Other Autoimmune Diseases
The combination of genomics, transcriptomics and proteomics sheds light on autoimmune thyroid disease, other autoimmune diseases and AML REYKJAVIK, Iceland, June 24, 2020 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare s...
Lowering LDL Levels with Repatha(R) (evolocumab) Did Not Adversely Affect Cognitive Function in Landmark Phase 3 Study
- Repatha Cognitive Function Trial Evaluated Subset of Patients From Cardiovascular Outcomes Trial - No Signal for Worsening Cognitive Function Observed Even in Patients Who Reached LDL Cholesterol Below 25 mg/dL - Detailed Results From One of the Largest Randomized, Controlled Studies of Cogn...
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
- Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent - Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively - Patients in Study had History of Heart Attack, Stroke or ...
Amgen Opens Next-generation Biomanufacturing Facility in Singapore
SINGAPORE, Nov. 20, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) has completed construction of its first Next-Generation Biomanufacturing facility, located in Singapore, heralding a new stage of efficient and innovative production of medicines that treat serious diseases. Biologic medicines are produ...
